CDK4 and hypogonadism: Novel targeted agents, including PARP and CDK4/6 inhibitors, pose further issues by compromising follicular integrity and granulosa cell functionality (56, 57), whereas immunotherapies and checkpoint inhibitors may induce primary or secondary hypogonadism (58, 59).